EML4 and non-small cell lung carcinoma: Given that EML4-ALK is the most common ALK fusions in NSCLC, several studies demonstrated that different variants of EML4-ALK fusions have distinct sensitivity to ALK inhibitors (18, 19), although some researchers found there was no significant differences in PFS among patients with these EML4-ALK variants (20).